SCIENTIFIC RESEARCH OF PROCONT

In 2000-2003, preclinical studies of the active substance of the product named Procont were conducted. They were held at the Accredited Toxicology Laboratory in Hungary.

We examined the active substance on five types of cancer: sarcoma, colorectal carcinoma, breast cancer, lymphoid leukemia, and melanoma. And we got positive results in all five areas.

In the course of our experiments, we tested three methods of taking the Procont active substance: subcutaneous, that is, in the form of an injection, intraperitoneal, and oral.

As a result, oral method was most effective. Therefore, it was decided to release this product in capsule form.

Also, we made the main conclusions, starting from two factors: the survival rate and the average tumor mass.

News

ALL NEWS

2020.07.07

HOW TO PROTECT YOURSELF FROM CORONAVIRUS?

The most effective way (in addition to observing basic hygiene standards) is to strengthen the immune system. It is known...
MORE
2020.07.07

SARCOMA

One of the groups of malignant tumors that we investigated. After taking Procont, we got the following results: – With...
MORE
2020.07.07

SCIENTIFIC RESEARCH OF PROCONT

In 2000-2003, preclinical studies of the active substance of the product named Procont were conducted. They were held at the...
MORE
2020.07.06

MEDICAL CONFERENCE IN UKRAINE

In April of this year, we successfully held a conference in Hungary with the participation of experienced doctors from Ukraine....
MORE